What is the role of netilmicin in the treatment of chronic bacterial prostatitis (CBP)?

Updated: Jan 15, 2019
  • Author: Samantha D Kraemer, MD; Chief Editor: Edward David Kim, MD, FACS  more...
  • Print

In a study of 78 men with fluoroquinolone-resistant CBP or contraindications to fluoroquinolone therapy, Vittorio et al reported that intramuscular netilmicin once daily for 4 weeks produced a 78.6% eradication rate and significant reductions in the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) score at 6-month and 12-month followup in those with eradicated infections. Genetic testing for deafness-predisposing mitochondrial mutations guided safer administration and overall therapy was well tolerated. [46] Further randomized controlled studies are needed to verify aminoglycosides as a therapeutic alternative.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!